Research Library — Page 2 | Reta Compare

59 research articles. Page 2 of 3.

Articles

• Compounded Tirzepatide and Pharmacy Benefit Managers
• Compounded Semaglutide and Tirzepatide: A Comparison
• Why Some Pharmacies Stopped Compounding Tirzepatide Voluntarily
• The Return of Tirzepatide Compounding: Will It Happen?
• FDA Removes Tirzepatide from Drug Shortage List (Recap)
• FDA Warning Letters on Compounded Tirzepatide in 2025 and 2026
• Overview of Eli Lilly's Lawsuits Against Compounded Tirzepatide
• Damages and Disgorgement in Lilly's Compounded Tirzepatide Cases
• Lilly's Settlement Patterns in Compounded Tirzepatide Cases
• Eli Lilly and the Lilly Patents Portfolio on Tirzepatide
• The Public Interest Defense in Compounded Tirzepatide Cases
• Eli Lilly's 10-K Disclosures on Compounded Tirzepatide Risk
• Lilly Advertising Campaign Against Compounded Tirzepatide
• Case Consolidation in Lilly Compounded Tirzepatide MDL Discussions
• Retatrutide vs Tirzepatide vs Semaglutide: Head-to-Head Trial Numbers
• Tirzepatide Research Chemical Pricing 2026
• Tirzepatide Shortage Timeline: Key Dates
• Evaluating the Efficacy of Retatrutide in Diabetic Kidney Disease Compared to Liraglutide and Tirzepatide
• Evaluating Retatrutide's Efficacy Against Tirzepatide in Obesity Management
• Comparing Retatrutide and Tirzepatide: Insights for Advanced Research
• Comparative Insights on Retatrutide for Weight Control Against Tirzepatide
• Retatrutide Demonstrates Superior Weight Loss in TRIUMPH-4 Trial Compared to Tirzepatide
• U.K. Regulators Target Illicit Production of Retatrutide and Tirzepatide
• Does Tirzepatide provide long-term cost-effectiveness for diabetes management?
• Can Tirzepatide improve outcomes in obesity-related heart failure?